Price Chart

Profile

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
URL https://www.regeneron.com
Investor Relations URL https://investor.regeneron.com/
HQ State/Province New York
Sector Health Care
Industry Biotechnology
Next Earnings Release May. 02, 2025 (est.)
Last Earnings Release Feb. 04, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Feb. 20, 2025

Profile

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
URL https://www.regeneron.com
Investor Relations URL https://investor.regeneron.com/
HQ State/Province New York
Sector Health Care
Industry Biotechnology
Next Earnings Release May. 02, 2025 (est.)
Last Earnings Release Feb. 04, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Feb. 20, 2025